Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANAB 
AnaptysBio Inc (ANAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ANAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $45.5
1 Year Target Price $45.5
| 7 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.31% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 558.62M USD | Price to earnings Ratio - | 1Y Target Price 45.5 |
Price to earnings Ratio - | 1Y Target Price 45.5 | ||
Volume (30-day avg) 12 | Beta -0.19 | 52 Weeks Range 12.21 - 40.70 | Updated Date 08/15/2025 |
52 Weeks Range 12.21 - 40.70 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.39 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -1.52 | Actual -1.34 |
Profitability
Profit Margin -107.66% | Operating Margin (TTM) -117.55% |
Management Effectiveness
Return on Assets (TTM) -14.12% | Return on Equity (TTM) -343.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 308006750 | Price to Sales(TTM) 4.54 |
Enterprise Value 308006750 | Price to Sales(TTM) 4.54 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA -1.3 | Shares Outstanding 27973000 | Shares Floating 16089855 |
Shares Outstanding 27973000 | Shares Floating 16089855 | ||
Percent Insiders 5.82 | Percent Institutions 132.67 |
Upturn AI SWOT
AnaptysBio Inc
Company Overview
History and Background
AnaptysBio, Inc. is a biotechnology company founded in 2005. It focuses on developing antibody therapeutics for inflammatory diseases. They've evolved from a technology platform company to a clinical-stage drug developer, experiencing successes and setbacks in their clinical trials.
Core Business Areas
- Antibody Therapeutics Development: AnaptysBio is focused on developing and commercializing novel antibody therapeutics for unmet medical needs in inflammation and immuno-oncology.
Leadership and Structure
The leadership team consists of executive officers with expertise in drug development, clinical trials, and business operations. The organizational structure is typical of a biotechnology company, with departments focused on research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Imsidolimab (anti-IL-36R antibody): Imsidolimab is AnaptysBio's lead clinical asset for treatment of generalized pustular psoriasis (GPP) and other IL-36 mediated diseases. Competitors include Boehringer Ingelheim's spesolimab (Spevigo) which is approved for GPP. Market share information unavailable.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long development timelines, regulatory hurdles, and intense competition. The inflammatory disease market is substantial, with significant unmet needs.
Positioning
AnaptysBio aims to be a leader in developing antibody therapeutics for inflammatory diseases by using its antibody discovery platform and clinical development expertise.
Total Addressable Market (TAM)
The TAM for IL-36 mediated diseases is estimated to be multi-billion dollars. AnaptysBio is aiming to capture a significant portion of this market through the successful development and commercialization of imsidolimab. Specific dollar value estimates vary based on disease prevalence, treatment costs, and market penetration assumptions.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platform
- Clinical stage assets
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Reliance on single lead product candidate
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Lack of approved products generating revenue
Opportunities
- Expansion of pipeline into new indications
- Partnerships and collaborations with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approval
- Increased awareness and diagnosis of target diseases
Threats
- Clinical trial failures
- Competition from other biotechnology and pharmaceutical companies
- Regulatory delays or rejection
- Patent challenges
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- LLY
- MRK
- BMY
- ABBV
Competitive Landscape
AnaptysBio competes with larger pharmaceutical companies with greater resources and established products. Its competitive advantage lies in its antibody discovery platform and focus on specific inflammatory disease targets. However, lack of currently approved products puts it at a competitive disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth analysis requires past revenue and earnings data which is not readily available in this model.
Future Projections: Future growth projections depend on clinical trial outcomes, regulatory approvals, and market penetration. Analyst estimates vary, and specific data is unavailable without accessing dedicated financial data platforms.
Recent Initiatives: Recent initiatives focus on advancing imsidolimab through clinical trials and exploring new indications for the antibody.
Summary
AnaptysBio is a clinical-stage biotechnology company focusing on antibody therapeutics for inflammatory diseases. The company's success hinges on positive clinical trial results for imsidolimab, its lead product candidate. A significant risk lies in its reliance on clinical trial success and the competitive landscape of larger pharmaceutical companies. While the antibody discovery platform is a strength, the lack of current revenue generation presents a challenge. Investors should closely monitor clinical trial progress and cash runway.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- News Articles
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share and financial data are estimates based on available information and may not be precise. Forward-looking statements are subject to risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AnaptysBio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2017-01-26 | President, CEO & Director Mr. Daniel R. Faga | ||
Sector Healthcare | Industry Biotechnology | Full time employees 136 | Website https://www.anaptysbio.com |
Full time employees 136 | Website https://www.anaptysbio.com | ||
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.